LFMD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

48.57M

-24.41%

-0.060

+200%

50.07M

-23.78%

-0.112

-1216.7%

53.73M

-13.64%

-0.105

+75%

Estimates Revision

The market is revising Downward the revenue expectations for LifeMD, Inc. (LFMD) for FY2025, with the revenue forecasts being adjusted by -6.46% over the past three months. During the same period, the stock price has changed by -45.59%.

Revenue Estimates for FY2025

Revise Downward

-6.46%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+5%

In Past 3 Month

Stock Price

Go Down

-45.59%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast LFMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFMD is 9.67 USD with a low forecast of 6.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 3.270

Low

6.00

Averages

9.67

High

15.00

Current: 3.270

Low

6.00

Averages

9.67

High

15.00

H.C. Wainwright

Yi Chen

Buy

downgrade

$13 -> $9

2025-11-19

Reason

H.C. Wainwright

Yi Chen

Price Target

$13 -> $9

2025-11-19

downgrade

Buy

Reason

H.C. Wainwright analyst Yi Chen lowered the firm's price target on LifeMD to $9 from $13 and keeps a Buy rating on the shares following a top- and bottom-line miss in Q3. LifeMD, which is now a pure-play telehealth and pharmacy platform after the company divested its majority ownership in WorkSimpli, updated its 2025 total revenue guidance and the firm adjusted its projections accordingly, the analyst noted.

KeyBanc

Scott Schoenhaus

Overweight

downgrade

$12 -> $8

2025-11-19

Reason

KeyBanc

Scott Schoenhaus

Price Target

$12 -> $8

2025-11-19

downgrade

Overweight

Reason

KeyBanc analyst Scott Schoenhaus lowered the firm's price target on LifeMD (LFMD) to $8 from $12 and keeps an Overweight rating on the shares. The firm notes LifeMD is being impacted by low-cost compounders despite the FDA outlawing the practice earlier this year. However, KeyBanc expects cash prices for brand-name GLP-1s to continue to come down as well as stricter enforcement against compounders in FY26, which should benefit LifeMD due to its partnerships with Eli Lilly (LLY) and Novo (NVO). The firm also expects the launch of oral Wegovy in early FY26 to drive higher weight management subscribers.

B. Riley

Buy

downgrade

$12 -> $10

2025-11-18

Reason

B. Riley

Price Target

$12 -> $10

2025-11-18

downgrade

Buy

Reason

B. Riley lowered the firm's price target on LifeMD to $10 from $12 and keeps a Buy rating on the shares. LifeMD reported a Q3 top- and bottom-line miss with lowered guidance for the telehealth business, largely due to increased competition from compounded GLP-1 providers, the analyst tells investors in a research note. LifeMD is well-positioned entering 2026 with multiple drivers of growth, including oral semaglutide launch expected in January, Medicare obesity coverage, 503(a) pharmacy expansion, and ramping women's health and behavioral health offerings.

Lake Street

Ryan Meyers

Buy

downgrade

$14 -> $8

2025-11-18

Reason

Lake Street

Ryan Meyers

Price Target

$14 -> $8

2025-11-18

downgrade

Buy

Reason

Lake Street analyst Ryan Meyers lowered the firm's price target on LifeMD to $8 from $14 and keeps a Buy rating on the shares. Q3 results reflect "operational progress," but a headwind from competitive pressures in the weight management business ultimately led to revised guidance for the standalone Telehealth business, the analyst tells investors. The firm is lowering its target based on revised estimates and a lower multiple.

BTIG

Buy

downgrade

$18 -> $10

2025-11-18

Reason

BTIG

Price Target

$18 -> $10

2025-11-18

downgrade

Buy

Reason

BTIG lowered the firm's price target on LifeMD to $10 from $18 and keeps a Buy rating on the shares. LifeMD's results reflected pressure on weight management from competitors who are offering lower-cost and potentially lower-quality compounded GLP-1 products, that are under-pricing more established platforms like LifeMD who more closely follow regulatory and quality protocols, the analyst tells investors in a research note. BTIG believes the headwinds and revenue lumpiness are temporary, and growth should reaccelerate in 2026.

H.C. Wainwright

Buy

downgrade

$14 -> $13

2025-08-07

Reason

H.C. Wainwright

Price Target

$14 -> $13

2025-08-07

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on LifeMD to $13 from $14 and keeps a Buy rating on the shares. The company reported a Q2 miss and reduced its outlook, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for LifeMD Inc (LFMD.O) is -9.19, compared to its 5-year average forward P/E of -18.69. For a more detailed relative valuation and DCF analysis to assess LifeMD Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-18.69

Current PE

-9.19

Overvalued PE

39.78

Undervalued PE

-77.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

6.48

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

17.21

Undervalued EV/EBITDA

-4.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.30

Current PS

0.00

Overvalued PS

2.34

Undervalued PS

0.27

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LFMD News & Events

Events Timeline

No data

News

9.5

11-22Benzinga

Benzinga Market Update: Nvidia, Webull, Netflix, and Tech Stocks Experience Largest Sell-Off Since April

6.0

11-19Benzinga

Eli Lilly Set for Over 12% Surge? Check Out 10 Leading Analyst Predictions for Wednesday

6.0

11-19Benzinga

HC Wainwright & Co. Reaffirms Buy Rating for LifeMD, Adjusts Price Target to $9

People Also Watch

Frequently Asked Questions

What is LifeMD Inc (LFMD) stock price today?

The current price of LFMD is 3.27 USD — it has decreased -3.82 % in the last trading day.

What is LifeMD Inc (LFMD)'s business?

LifeMD, Inc. is a provider of virtual healthcare services and pharmacy services. The Company offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The Company owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.

What is the price predicton of LFMD Stock?

What is LifeMD Inc (LFMD)'s revenue for the last quarter?

LifeMD Inc revenue for the last quarter amounts to 60.17M USD, increased 12.95 % YoY.

What is LifeMD Inc (LFMD)'s earnings per share (EPS) for the last quarter?

LifeMD Inc. EPS for the last quarter amounts to -0.10 USD, decreased -23.08 % YoY.

What changes have occurred in the market's expectations for LifeMD Inc (LFMD)'s fundamentals?

How many employees does LifeMD Inc (LFMD). have?

LifeMD Inc (LFMD) has 304 emplpoyees as of December 16 2025.

What is LifeMD Inc (LFMD) market cap?

Today LFMD has the market capitalization of 157.40M USD.